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Summary
The problem of interpreting missense mutations of dis-
ease-causing genes is an increasingly important one. Be-
cause these point mutations result in alteration of only
a single amino acid of the protein product, it is often
unclear whether this change alone is sufficient to cause
disease. We propose a Bayesian approach that utilizes
genetic information on affected relatives in families as-
certained through known missense-mutation carriers.
This method is useful in evaluating known disease genes
for common disease phenotypes, such as breast cancer
or colorectal cancer. The posterior probability that a
missense mutation is disease causing is conditioned on
the relationship of the relatives to the proband, the pop-
ulation frequency of the mutation, and the phenocopy
rate of the disease. The approach is demonstrated in two
cancer data sets: BRCA1 R841W and APC I1307K. In
both examples, this method helps establish that these
mutations are likely to be disease causing, with Bayes
factors in favor of causality of 5.09 and 66.97, respec-
tively, and posterior probabilities of .836 and .985. We
also develop a simple approximation for rare alleles and
consider the case of unknown penetrance and allele
frequency.
Introduction
The commitment of the genetics research community to
map the human genome and identify disease-causing
genes has been successful in advancing our knowledge
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in a number of areas, such as molecular technology lead-
ing to more-rapid cloning and sequencing of genes
(Guyer and Collins 1995; Schuler et al. 1996; Savill
1997). These major advances have opened other im-
portant areas of investigation, including biochemical
mechanisms for disease and genetic epidemiological im-
plications of newly discovered genes in patients and pop-
ulations (Ellsworth et al. 1997).
Of major importance is the interpretation of kinds of
mutations that occur in genes and whether they may be
involved in causation of disease (Cooper and Krawczak
1993). It is widely accepted that mutations that result
in frameshifts (insertions or deletions) can significantly
alter the protein product, as can point mutations that
result in splice-site alterations or stop codons (nonsense
mutations). A problematic type of point mutation is one
that results in a substitution of one amino acid for an-
other (missense mutation). These amino acid substitu-
tions can be disease causing if they affect an important
functional region of the protein. A well-known example
is the substitution of valine for glutamic acid in the b-
globin gene at the sixth codon, which results in an ab-
normal hemoglobin that is less soluble in deoxygenated
blood, the basic biochemical defect in sickle-cell anemia.
Alternatively, an amino acid substitution may occur in
a less critical or conserved region of the protein and may
be tolerated, such that it results in an isoform of the
protein and, genetically, is interpreted as an allelic var-
iant or possible polymorphism.
With the identification of disease-causing genes, a ma-
jor challenge to molecular geneticists is the detection and
characterization of mutations in affected persons (Cot-
ton 1997). The definitive methodology is DNA sequenc-
ing, which will identify point mutations, including mis-
sense mutations. The interpretation of a missense mu-
tation is often inconclusive as to whether it is disease
causing. In particular, when the mutation is frequent and
carriers exhibit lower penetrance, it poses a greater chal-
lenge because one could argue that it is a polymorphism.
We present a method that utilizes a Bayesian approach
for families with multiple affected persons, to establish
statistically whether a missense mutation in an autoso-
mal dominant gene is disease causing. We apply this
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method to published data on a missense mutation of the
adenomatous polyposis coli (APC) gene in familial colon
cancer (Laken et al. 1997) and a missense mutation of
BRCA1 in hereditary breast cancer (Barker et al. 1996).
Methods
Study Design
We propose a study design based on testing affected
relatives of probands who are known to be carriers of
the missense mutation. This design is efficient and pro-
vides meaningful information about the association
when there is good a priori information about the rate
of sporadic disease in the population and about the pop-
ulation frequency of the mutation. If the missense mu-
tation is not disease causing, we expect to observe a
proportion of positive affected relatives that is dictated
simply by the degree of relationship between the relatives
in the sample and the proband. For example, among
first-degree relatives of heterozygous carrier probands of
a rare mutation, we would expect about one-half to be
carriers. If the mutation is disease causing, we expect to
see an increased proportion, beyond one-half, depending
on the penetrance and the phenocopy rate. Our ap-
proach quantifies how many more to expect and weighs
the evidence in favor of causality.
In addition to its practical and ethical advantages, a
design based on testing only affected relatives can be
statistically efficient when reliable information about
phenocopy rates is available. Swift et al. (1990) studied
a simpler design in which a single affected relative per
proband is tested, and developed a large-sample ap-
proximation of the confidence interval of the odds ratio
of a genotype, given the disease status. They also com-
pared the statistical efficiency of affected-only designs
with that of case-control designs, in which unaffected
relatives also are tested, and concluded that if the disease
incidence among noncarriers is known with reasonable
accuracy, testing only those affected is substantiallymore
efficient. Although our design is more general, their over-
all conclusions about efficiency are likely to be applicable
here.
Sampling Distributions
We consider an autosomal dominant gene and focus
on a single, potentially disease-causing allele (i.e., a mis-
sense mutation in a disease-causing gene). We assume
that the allele frequency in the population is known, and
we denote this as “p,” with We also assume1 p  q.
that the rate of disease among noncarriers (the pheno-
copy rate) and the penetrance among carriers are known.
We define the penetrance as b  P (diseaseFAA) 
and the phenocopy rate asP (diseaseFAa) J 
. We are interested in whether the allele isP(diseaseFaa)
disease causing—that is, in whether carriers of the allele
are at increased disease risk. The presence of a causal
effect is denoted by the variable C, with if theC  1
disease is caused by the mutation and if it is not.C  2
So corresponds to , whereas corre-C  1 b 1 J C  2
sponds to . The Appendix extends our approachb  J
to the case of unknown reduced penetrance and un-
known allele frequency, with a known rate of disease
for the overall population.
To assess the presence of a causal effect, we compute
the Bayes factor for versus and the a pos-C  1 C  2
teriori probability that the allele is disease causing, given
the observed mutation-test results from one ormore ped-
igrees. If the penetrance, prevalence, and phenocopy rate
are known, the Bayes factor is simply the ratio of the
likelihoods of the observed testing results under the two
hypotheses. However, by use of a Bayesian approach,
extensions to unknown penetrance, prevalence, and phe-
nocopy rate are straightforward.
For K probands, with genotypes , whereg ,) ,g01 0K
is either AA or Aa and is fixed by design, we haveg0k
corresponding affected relatives who are tested fornk
the same mutation. The genotype of relative i of proband
k is and can be AA, aa, or Aa. The calculations aregik
also conditioned on the relationship to the proband. To
keep the notation concise, we refer to the vector of the
genotypes for the relatives of proband k as g k
. Because of the study design, all probabil-(g ,) ,g )1k n kk
ities are implicitly conditional on the proband’s geno-
type, on the relative being affected, and on his or her
degree of relationship to the proband.
We begin by considering the contribution of a single
family in the sample. To evaluate this, we need to be
able to evaluate the probabilities P(observed genotypes
of relativesFC) for all possible combinations of observed
genotypes and C. If the mutation is not disease causing
( ), the conditional probability of observed geno-C  2
types of relatives in family k is
g { P(g Fg , C  2)  P(g Fg ) , (1)noncausal,k k 0k k 0k
because affected status does not carry any information
about genotype probabilities. depends on theP(g Fg )k 0k
allele frequency p and also on the degree of relationship
to the proband, which is not explicitly incorporated into
the notation but is considered in the calculation, and it
can be determined simply on the basis of the degree of
relationship to the proband, by use of standard condi-
tional probability arguments (Elandt-Johnson 1971).
For example, if proband k is Aa and his or her family
contains only one other affected relative, a sibling also
with genotype Aa, then andn  1k
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1P(g Fg , C  2)  P(AaFAa, C  2)  (1 pq) .1k 0k 2
For a heterozygous parent of the proband, we would
have
1P(g Fg , C  2)  P(AaFAa, C  2)  ;1k 0k 2
for a homozygous sib,
1P(g Fg , C  2)  P(AAFAa, C  2)  p(1 p) ;1k 0k 4
and so forth. A general algorithm is presented by Li and
Sacks (1954). The software package LINKAGE (Genetic
Linkage Analysis, Laboratory of Statistical Genetics,
Rockefeller University) can be used to automate these
calculations.
If the mutation is disease causing ( ), the ex-C  1
pected fraction of carriers among affected relatives is
higher than if it is not disease causing. Conditional on
a genotype vector with relatives with aa genotypeaag nk k
and under the assumption that the disease outcomes of
relatives are independent given their genotypes, the
probability that all relatives have the disease is
. By use of the genotype probabilities
aa aan n nk k kJ b P(g Fg )k 0k
as priors, we can determine genotype probabilities under
via Bayes rule. For the case, the probabilityC  1 C  1
of the observed genotypes of relatives in family k is
g  P(gFg , C  1)causal,k 0k
aa aan n nk k kP(g Fg )J bk 0k , (2)aa aan n ng k g P(gFg )J bg 0k
where ranges over all possible genotype combi-k 3g
nations and is the number of aa elements in the vectoraang
. In practice, the number of terms in the summation ing
the denominator can be reduced by factoring terms that
lead to the same value of . For example, for a probandaang
with one sibling who is Aa, we have
P(g Fg , C 1) P(AaFAa, C 1)1k 0k
P(AaFAa)P(diseaseFAa or AA)





When the disease has a variable age at onset and when
the age-at-onset data for relatives are available, b and
J should be specified in terms of age-specific survival
contributions. This would entail taking each subject’s
age into account. However, by rewriting expression (2)
as
aank( )P(g Fg ) J/bk 0k
g  ,aacausal,k ng( ) P(gFg ) J/bg 0k
it can be seen that depends on b and J only viagcausal,k
their ratio and therefore is valid as long as the ratio of
the penetrance to the phenocopy rate remains constant
with respect to age. It is possible to carry out an age-
dependent analysis along the lines of the approach de-
scribed here. However, this requires either a large num-
ber of observations or good a priori knowledge of the
penetrance function for the mutation under considera-
tion. These were not available for the applications con-
sidered in this article.
Probability of a Disease-Causing Effect
We can now evaluate the probability of a causal effect
conditional on the observed mutation tests in the af-
fected relatives (“data”). Because the families can be con-
sidered independent, in our case
K
P(dataFC  1) g andcausal,k
k1
K
P(dataFC  2) g ,noncausal,k
k1
so that the Bayes factor in favor of the hypothesis of
causality is
K gk1 causal,k
B  .K gk1 noncausal,k
Using expressions (1) and (2) and algebraic manipula-
tion, we can express the Bayes factor simply in terms of
the genotype coefficients and the penetrance-to-pheno-
copy rate ratio:
K aa aan ng kJ
1/B  P(gFg ) . 0k ( )
k1 bg
This incorporates the dependence among relatives of the
same proband and the possibility that there is more than
one copy of the mutated allele in the same family.
By using Bayes rule, which states
P(C  1Fdata)
P(C  1)P(dataFC  1)
 ,
P(C  1)P(dataFC  1) P(C  2)P(dataFC  2)
and by denoting the a priori odds in favor of causality
by , the posterior probability ofO  P(C  1)/P(C  2)
causality is .P(C  1Fdata)  OB/ (OB 1)
The choice of a priori odds can be important and must
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Table 1














Aa, Aa, Aa .42 .08 5.02
2 Sibling Aa .81 .52 1.56
3 Mother Aa .79 .50 1.58
4 Sibling aa .18 .47 .38
5 Sibling Aa .81 .52 1.56
6 Grandmother Aa .61 .28 2.15




Aa, Aa .70 .26 2.72
NOTE.—Summary of genetic-testing results and contributions of
each family to the likelihood ratio. The rightmost column represents
the contribution of each family to the calculation of the Bayes factor,
which is the product of the values in the column.
reflect the context of the analysis. If the mutation was
selected because it resides on a known disease-causing
gene, the prior odds may be high, while, when screening
for a disease-causing mutation, a low population-based
prior probability of causality may be more appropriate.
In any case, analysis of the Bayes factor gives a measure
of the weight of evidence of the data in favor of the
hypothesis that does not require specification of prior
odds. Kass and Raftery (1995) give an in-depth discus-
sion of interpretation and calibration of Bayes factors.
A convenient option is the assumption of P(C  1) 
, which gives —that is, even a priori odds to the1 O  12
hypothesis of causality.
Results
Familial Breast Cancer and BRCA1 R841W
We investigate the causality of the BRCA1 R841W
mutation, using two pedigrees from the study by Barker
et al. (1996). The disease phenotype of interest is either
breast or ovarian cancer. There are probands whoK  2
have tested, affected relatives. Proband 1160 has one
heterozygous sibling affected with breast cancer, g 1
. Proband 728 has two heterozygous siblingsg  Aa11
affected with breast cancer. Thus, g  (g ,g ) 2 12 22
. We assume a phenocopy rate , a pen-(Aa,Aa) J  .125
etrance , indicated as plausible for other BRCA1b  .85
mutations (Ford and Easton 1995), and an allele fre-
quency . Evidence for the estimation of age-p  1/100
specific penetrance for this specific mutation was insuf-
ficient. Our calculations are based on the assumption
that the ratio of penetrance, for carriers and non-b/J
carriers, does not depend on age. We will later assess
sensitivity to p and . Not all affected family membersb/J
were tested; we assume that the reason why they were
not tested is unrelated to their genotype.
By use of expressions (1) and (2),
1
g  (1 pq)  .505 ;noncausal,1 2
1 2 2g  (5pq p  q )  .257 ;noncausal,2 4
1
g  g /[1 q(1 q)(1 J)]  .871 ; andcausal,1 noncausal,1 4
1 1 252 2 2g  g /{ q(1 q)J  p  q  pqcausal,2 noncausal,2 8 4 16
1 1 252 2 [1 q(1 q) p  q  pq]J}8 4 16
 .761 .
The evidence from family 1 is ∼1.73# more likely
under the hypothesis of causality. The evidence from
family 2 is 2.96# more likely under the hypothesis of
causality. This results in a Bayes factor of 5.09, indi-
cating that test results from the two families are ∼5#
more likely under the hypothesis of causality than under
the hypothesis of no causality. If prior odds for causality
are even, the posterior probability of causality is .836.
Our results are virtually unchanged as p varies over
the range 0–.01 and decreases to .82 if p is set to .05.
The rare-allele approximation discussed in the Appendix
gives virtually the same results. The results are only
mildly sensitive to assumptions about penetrance. At a
penetrance of 1, the probability of causality is .85. At a
penetrance of .5, it is .8.
Familial Colon Cancer and APC I1307K
Mutations of the APC gene can be associated with
increased risk of colorectal cancer and colorectal ade-
nomas. We investigate the causality of mutation TrA
at APC nucleotide 3920, using eight pedigrees reported
by Laken et al. (1997). We used a disease rate a of .2,
on the basis of clinical judgment, and an allele frequency
p of the mutation of .036, on the basis of table 1 in the
report by Laken et al. (1997); we estimated allele fre-
quencies separately in the disease group and control
group, and combined the two estimates using the pos-
tulated value of a. Expressions (1) and (2) were com-
puted for each proband. The results are summarized in
table 1.
The resulting Bayes factor is 66.97, which is strong
evidence in favor of causality. The posterior probability
under even prior odds is .985. The rare-allele approxi-
mation discussed in the Appendix produces a Bayes fac-
tor of 194.90, leading to a posterior probability of .995.
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Figure 1 Posterior distribution of penetrance parameter b
Because the mutation is relatively common, the rare-
allele approximation does not work as well as in the
breast cancer example. Also, use of expression (A3) leads
to ignoring the dependence between proband 8’s sibling
and that sibling’s offspring and therefore is not appro-
priate in this case.
Following the development discussed in the first sec-
tion of the Appendix, we also conducted an analysis with
unknown penetrance and allele frequency. We assumed
that causality ( ) corresponds to , and we as-C  1 b 1 J
sumed that, if the mutation is indeed causal, then all
values of b are equally likely a priori. With regard to p,
we used information from table 1 in the report by Laken
et al. (1997) to specify a prior on the fraction of carriers
and then converted that into a distribution for p. Because
the fraction of diseased individuals in the sample ap-
proximates the overall population fraction, we com-
bined diseased and nondiseased individuals when spec-
ifying our prior. The resulting specification is p  1
, where r has a beta distribution with para-1/2(1 r)
meters and .47 22  69 766 211 47 22  908
To analyze the effect of uncertainty about b and p on
the Bayes factor and posterior probability of , weC  1
first computed the a posteriori probability distribution
. This inference is conditional on thep(b,pFdata, C  1)
assumption of uninformative ascertainment, which may
be violated in this data set. Although inference of the
penetrance and prevalence is not the focus of the meth-
odology proposed here, incorporation of uncertainty via
is an effective strategy to make in-p(b,pFdata, C  1)
ferences about causality without relying on strong as-
sumptions of b and p. To illustrate the range of plausible
values of b, figure 1 graphs the a posteriori probability
distribution of b conditional on . For the pur-p  .035
pose of testing for causality, the important aspect of this
distribution is that it assigns very low probability to
values close to the phenocopy rate and high probability
to values far away from it, so that, even though the
actual magnitude of b is not accurately estimated, reli-
able conclusions about causality can be reached. We
computed the Bayes factor and posterior probability of
using expression (A2). The Bayes factor is 53.21,C  1
and the resulting posterior probability is .982. Even in
the presence of substantial uncertainty about the exact
value of the prevalence parameter, the evidence in favor
of causality in this example remains strong. Results are
somewhat sensitive to the specification of the phenocopy
rate a, but the evidence in favor of causality is not ques-
tioned within a broad range of values. At , thea  .1
posterior probability is .987, whereas at it is .965.a  .3
Discussion
We propose an approach, using Bayesian methods, to
statistically determine whether a missense mutation in
an autosomal dominant disease gene is likely to be dis-
ease causing. Our method is particularly useful in eval-
uating common disease phenotypes, only a small pro-
portion of which may be caused by known disease-
causing genes, such as those for hereditary breast cancer
or familial colorectal cancer. This approach employs the
testing of other affected relatives for the missense mu-
tation in pedigrees that have been identified through a
proband with the missense mutation. The posterior
probability that the mutation is disease causing is con-
ditioned on the relationship of the relative to the pro-
band, the frequency of the mutation, and the phenocopy
rate of the disease. Because only affected relatives are
selected for genetic analysis, this method is efficient,
from the perspective of conducting a study. Because un-
affected relatives are not studied, this method avoids the
pitfalls that relate to recruitment of such persons for
research in the current genetic-testing environment
(Hubbard and Lewontin 1996; Geller et al. 1997; Holtz-
man et al. 1997).
However, by limiting analysis only to families with at
least two affected relatives, there is a potential for biasing
the conclusion in favor of causality, since the penetrance
may, in reality, be lower than the sample indicates. This
can be partially addressed by varying penetrance esti-
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mates in the computations. This design element alsomay
affect our results if there is a sizable proportion of fam-
ilies that have only one affected person (the proband).
If the unaffected phenotypes in these families are caused
by reduced penetrance, the magnitude of the effect for
specific mutations may be empirically assessed only by
genotyping unaffected relatives. This design modifica-
tion, of course, engenders logistical issues for the exe-
cution of the study.
Another important consideration is the potential bias
that may occur in the selection of affected relatives for
genotyping. Our approach assumes that inclusion in the
study is unrelated to genotype. Ideally, any and all af-
fected biological relatives should be genotyped, but
availability of DNA can be affected by numerous factors
(relatives who are deceased or who are unable or un-
willing to participate). If availability for study is non-
random, for whatever reasons, this may have an effect
on the posterior probability, but the effect would depend
on the nature of the selection bias.
We have shown that this method can be applied use-
fully to empirical data. We analyzed families identified
through probands with the APC I1307K mutation
(Laken et al. 1997), in which 10 of 11 affected relatives
tested positive for the same mutation, including three
second-degree relatives. We found a .985 posterior prob-
ability that the APC I1307K mutation is causally related
to the colorectal neoplasia in these families. In the case
of BRCA1 R841W (Barker et al. 1996), there were fewer
families and persons studied, but we estimated a .836
posterior probability that this missense mutation may
be causally related to breast cancer or ovarian cancer in
these families.
These two examples contrast another challenge in the
interpretation of missense mutations—namely, a plau-
sible mechanism of disease causation engendered by the
mutation (Ellsworth et al. 1997; Fearon 1997). In the
case of APC I1307K, the TrA transversion in the APC
gene results in an tract, which appears to engender8(A)
an inherent instability in the gene, allowing deleterious
mutations to occur in this critical gene during subsequent
cell division (Laken et al. 1997). In the case of BRCA1
R841W, however, it is difficult to posit a plausible mech-
anism because the function of the gene remains unclear.
Our proposed method may provide additional evidence
to support a disease-causing missense mutation in such
cases. That a missense mutation may have a plausible
mechanism for causing disease can justify a more real-
istic estimate of the penetrance (whether higher or
lower), whereas a missense mutation in a gene of un-
known function may conservatively be justified to be
lower.
There is a possibility, although remote, that the mis-
sense mutation may be in linkage disequilibrium with a
“true” deleterious mutation elsewhere in the allele. Con-
sidering the way in which many missense mutations are
identified through DNA sequencing, such a possibility
would have been uncovered. In the case of our colon
cancer example, Laken et al. (1997) reported that the
APC I1307K–bearing alleles in two carriers were fully
sequenced and that no other mutations were detected.
This approach is predicated on the assumption that a
single missense mutation has been singled out for par-
ticular attention, on a priori grounds. Since disease genes
may potentially be highly polymorphic, additional com-
plications arise for the interpretation of the causality of
polymorphisms that may come to attention because of
their frequency in multiple case families, since such pol-
ymorphisms are more likely than randomly selected pol-
ymorphisms to appear to be causal, even if C  2 were
true. A hierarchical Bayesian treatment of this problem
might entail simultaneous consideration of all known
polymorphisms, with additional parameters for varia-
tion in b and p between polymorphisms. The model
could include “prior covariates,” such as the position in
the gene or the nature of the particular amino acid sub-
stitution that results, for which the effects on penetrance
are to be estimated empirically. Such an analysis is be-
yond the scope of this article, but similar methods have
been applied in the treatment of multiple-exposure prob-
lems in epidemiology (Greenland 1993) and gene-envi-
ronment interactions (Aragaki et al. 1997).
The design approach of the study of affected relatives
of a proband was employed by Swift et al. (1990) and
was applied by Athma et al. (1996) in a study of breast
cancer risk in ataxia telangiectasia heterozygotes. This
approach differs from the method proposed here, in a
number of elements. Their design requires ascertainment
of one affected relative of an index carrier (who may
not be affected with the disease of interest) per family.
Inference and testing are based on a large-sample ap-
proximation of the confidence interval on the odds ratio
of the genotype, given the disease status. An important
advantage of the Bayesian approach is that it is simple
to derive inferences, without having to rely on large-
sample approximations that could be inaccurate, and it
is straightforward to incorporate uncertainty about un-
known additional parameters, as discussed in the
Appendix.
Finally, we have developed a simple program in S-
PLUS, shown in the Appendix, which provides com-
putation of the Bayes factor and posterior probabilities
in the rare-allele case. This basic approach can be ex-
tended to consider reduced penetrance with variable age
at onset and errors in genetic testing. Development of
these extensions is currently in progress.
Conclusions
The approach proposed here anticipates one of the
outgrowths of the Human Genome Project and genetic-
1522 Am. J. Hum. Genet. 62:1516–1524, 1998
disease research: a number of families that segregate
common disease phenotypes may be identified to carry
missense mutations of known disease-causing genes. A
concomitant problem in interpretation of the signifi-
cance of the missense mutations is determination of
whether they are disease causing or simple polymor-
phisms. We have developed a logistically efficient and
computationally feasible approach that may more
quickly help determine the importance of such
mutations.
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Appendix
Statistical Details
Unknown Penetrance and Prevalence
The derivation of the posterior probability of a causal
effect can be extended to the case of unknown pene-
trance and prevalence parameters. Within a Bayesian
approach, this is carried out by replacing the fixed values
of b and p with prior probability distributions reflecting
information from prior studies or other biological evi-
dence. The prior distribution of the unknown b and p
is denoted here by . If the penetrance of a similarp(b,p)
mutation has been previously studied, published data
can be used to specify an informative prior for b. Oth-
erwise, an attractive option is to assume a priori that all
values 1J are equally likely, leading to p(b)  1/(1
, . Because the mutation may be responsibleJ) J ! b X 1
for a nonnegligible fraction of the overall cases, the as-
sumption that J is known also needs to be relaxed. Here,
we assume that the overall incidence a is known. The
overall incidence depends on J, b, and p, via the rela-
tionship , leading to2 2a  q J (1 q )b J  [a
.2 2(1 q )b] /q
As in the section Sampling Distributions, under C 
it is natural to assume that . With this specifi-1 b 1 J
cation, then, we are testing a point null hypothesis
against a composite alternative hypothesis. Berger and
Delampady (1987) review the Bayesian approach to this
problem and compare it with frequentist approaches.
For a fixed a, a prior distribution of b and p implies a
prior distribution of J. Also, whenever .J ! b a ! b
Under these assumptions, expression (1) remains the
same, whereas expression (2) can now be interpreted as
conditional on b and p; that is,
g (b,p)  P(gFg , C  1,b,p)causal,k 0k
aa aan n nk k kP(g Fg )b Jk 0k ; (A1)aa aan n nk g g P(gFg )b Jg 0k
rewriting J in terms of a, b, and p,
aa2 2 nk[ ]P(g Fg ){a (1 q )b /q b}k 0k
g (b,p)  ,aacausal,k 2 2 ng[ ] P(gFg ){a (1 q )b /q b}g 0k
so that .KP(dataFC  1)   g (b,p)k1 causal,k
The Bayes factor for the hypothesis of causality is now
1 1 K g (b,p)p(b,p)dbdp∫ ∫0 a k1 causal,k
B  , (A2)K gk1 noncausal,k
and the posterior probability incorporating uncertainty
about b and p can be derived in the usual way as
, where O is the priorP(C  1Fdata)  OB/(1OB)
odds in favor of . Expression (A2) is easily eval-C  1
uated numerically by use of a Monte Carlo approach.
To evaluate the numerator, it is sufficient to generate a
sample for the prior distribution and to computep(b,p)
the average of the resulting values of .K g (b,p)k1 causal,k
Expression (A1) can be used to derive an a posteriori
distribution on b and p, conditional on :C  1
K g (b,p)p(b,p)k1 causal,k
p(b,pFdata,C  1)  .1 1 K g (b)p(b,p)dbdp∫ ∫0 a k1 causal,k
This provides a valid inference on the penetrance if it
can be assumed that the selection mechanism—that is,
choosing families with at least one affected relative and
eliminating index cases—is not inducing a bias in the
estimation of penetrance.
Rare Alleles
When the allele is rare and there are no homozygous
carriers in the sample, ignoring the dependence among
relatives of the same proband and ignoring the possi-
bility that there is more than one copy of the mutated
allele in the same family have a limited impact on the
final answer. Expressions (1) and (2) then can be sim-
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Figure A1 S-PLUS function for computing the Bayes factor and
posterior probability of a disease-causing effect, for the rare-allele case.
This function is available at http://www.isds.duke.edu/˜gp.
plified considerably. It is interesting to study the form
of these simplified expressions. All the relativesN   nk
can be considered to be approximately independent. For
relative j, let be the degree of relationship to the pro-rj
band and be an indicator variable of whether or nothj
relative j is a carrier. Then
N
1hr h r j1 j j 1 jP(dataFC  2) ≈ 1( ) ( )[ ]2 2
j1
N r 1hj j(2  1)
 .rjj1 2
Applying Bayes rule for each individual and using in-
dependence, we also obtain
r h h r 1hj j j j jN ( ) ( )1/2 b 1 1/2 J[ ]{ }
P(dataFC  1) ≈ r rj j( ) ( )j1 1/2 b 1 1/2 J[ ]
N h r 1hj j jb [(2  1)J]
 .rjj1 1 (2  1)J
After some simple manipulations, these lead to a Bayes
factor in favor of a causal effect of
h rj jN ( )b/J 2
B  . (A3)rj( )j1 b/J 2  1
Each of the N terms is the ratio of the probability of
the evidence under to the probability of the ev-C  2
idence under , or the weight of evidence againstC  1
. For example, for a first-degree relative, the ratioC  2
is , which is 11, if the relative is a carrier; and2b/(b J)
the ratio is , which is !1, if the relative is not2J/(b J)
a carrier.
In the unknown penetrance case, the expression for
the Bayes factor becomes
1
h rj jN ( )b/J 2
B   p(b)db . rj( )j1 b/J 2  1
a
A function evaluating this expression by use of a Monte
Carlo algorithm is provided in figure A1. In the rare-
allele case, it is simple to develop general-purpose func-
tions for computing the Bayes factors and the posterior
probability of causality. Here we present a function,
written in the statistical package S-PLUS, that handles
both the known and unknown penetrance cases (this
function is available at http://www.isds.duke.edu/˜gp).
The inputs to the function are the following: the vector
RELATIONS, with as many elements as there are rel-
atives and with each element a 1, 2, etc., for first-degree
relatives, second-degree relatives, etc.; the vector GEN-
OTYPES, again with one element for each relative, either
0 if the relative is aa or 1 if the relative is Aa (use of
the rare-allele approximation is not recommended when
there are homozygous relatives in the sample); the scalar
PREVALENCE, for the value of the prevalence, if
known; the Boolean variable UNKNOWN.PREV-
ALENCE, which can be set to T or F, depending
on whether the penetrance is known (if UN-
KNOWN.PREVALENCE is set to T, the input value of
PREVALENCE is ignored); and the integer MONTE-
CARLO, specifying the number of Monte Carlo samples
desired in the evaluation of the Bayes factor when the
penetrance is unknown.
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